Evaluation of the time to clinical recovery in the case with Dinvl in moderate-intensity pneumonia caused by Corona 19 compared with the control group
Design
Randomized single blind, phase 3 clinical trial on 60 patients, The random number table was used for randomization
Settings and conduct
This study was performed in hospitals, Baqiat Allah, in Tehran, on patients with moderate-intensity pneumonia caused by covid 19.
Participants/Inclusion and exclusion criteria
Inclusion criteria up18 year-olds with moderate-intensity pneumonia caused by Covid 19 whose disease has been proven on the basis of CT scan or PCR evidence and have signed a participation form. Exclusion criteria All people who are prohibited from taking Dinvl or similar compounds or who are likely to have severe side effects if taken Dinvl.
Intervention groups
Patients with inclusion criteria in the intervention group, in addition to the usual treatment, are treated daily with dinvl for 7 consecutive days. In the control group, the usual treatment for covid 19 infection.
Main outcome variables
Time to clinical recovery 14 days readmission Rate Time to intubation Intubation rate 28 days survival rate side effects caused by dinvl
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20200509047373N1
Registration date:2020-05-23, 1399/03/03
Registration timing:prospective
Last update:2020-05-23, 1399/03/03
Update count:0
Registration date
2020-05-23, 1399/03/03
Registrant information
Name
Ahmad Hosseinpour
Name of organization / entity
Health Medicine Chemistry Company
Country
Iran (Islamic Republic of)
Phone
+98 71 3739 1910
Email address
ahosseinpour3@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-06-03, 1399/03/14
Expected recruitment end date
2020-08-20, 1399/05/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation effects of DINVL herbal medicine on the recovery of patients with COVID - 19
Public title
Evaluation effect of Dinvl for Covid19 infection
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients up18 years old hospitalized
Patient with SpO2:85-89% on room air at admission (if correct with nasal O2 maximum 6 liter/min to SpO2>=90 )
Patients with SpO2: 90-93% and RR>=30 clinical compatible
patients with positive RT-PCR test or consistent HRCT to covid19
pneumonia Sign the study participation form
Exclusion criteria:
Known sensitivity to plant compounds.
Pregnant woman Lactating woman Patients with active peptic.
Age
No age limit
Gender
Both
Phase
2-3
Groups that have been masked
Participant
Investigator
Outcome assessor
Data and Safety Monitoring Board
Sample size
Target sample size:
60
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, the random number table method is used for randomization.The randomization unit is also the individual.To read numbers, it is also from left to right.For concealment, the method of sequentially numbered, sealed, opaque envelopes is used.
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, patients, the main researcher, the physician who visits patients daily for response to the treatment and examination of symptoms, and is responsible for collecting information, and the nursing staff are kept blind to the allocation of study groups.All patients are visited daily by one of the physicians of the treatment team who is in the process of intervention.However, the follow-up of the side effects of the drug and the evaluation of the course of treatment in patients will be performed by another physician, who is also in the general study constant.This physician will monitor the condition of patients at home for up to 4 weeks after discharge and will be completely blind.
Placebo
Not used
Assignment
Parallel
Other design features
In this study, patients with admission conditions were divided into two groups. In addition to the usual treatment for coronavirus infection, the intervention group received Dinvl daily for 7consecutive days, but the control group received only routine treatment for corona infection .
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Medical Ethics Committee of Baqiyatallah University of Medical Sciences
Street address
Baqiyatallah University of Medical Sciences, Molla Sadra Street
City
Tehran
Province
Tehran
Postal code
1435915371
Approval date
2020-05-09, 1399/02/20
Ethics committee reference number
IR.BMSU.REC.1399.154
Health conditions studied
1
Description of health condition studied
Pneumonia induced by covid19
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified
Primary outcomes
1
Description
Time to clinical recovery
Timepoint
Control clinical signs daily until discharge from the hospital
Method of measurement
Fever control with thermometer, oxygen saturation control with pulsoximetry
Secondary outcomes
1
Description
14 days readmission after discharge.
Timepoint
Up to 14 days after discharge
Method of measurement
All patients will be given a contact number to notify them if they are hospitalized again. All patients will be monitored by phone weekly for up to 4 weeks after the first day they are admitted.
Intervention groups
1
Description
Intervention group:ُُDinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company
Category
Treatment - Drugs
2
Description
Control group: Routine tablets is given daily for seven days
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
All participants' data is shared after it becomes unrecognizable
When the data will become available and for how long
Data access starts immediately after printing the results
To whom data/document is available
The data in this study are only available to medical researchers
Under which criteria data/document could be used
It is available for any analysis or use that aims to improve and progress in the treatment of covid19 infection
From where data/document is obtainable
Contact email address:ahisseinpour3@gmail.com
What processes are involved for a request to access data/document
In case of requesting data for the study, the applicant must first introduce himself or herself and the relevant organization to determine the purpose of the data request and state for what purpose this data is used.After submitting the request, if the researchers of this study prove that the data of this study can advance the therapeutic goals, the information will be sent as long as the data remains confidential.This process takes two weeks.